- Open Access
SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma
- Yi Xu†1,
- Yue Yao†2,
- Xingming Jiang†1,
- Xiangyu Zhong1,
- Zhidong Wang1,
- Chunlong Li1,
- Pengcheng Kang1,
- Kaiming Leng1,
- Daolin Ji1,
- Zhenglong Li1,
- Lining Huang1,
- Wei Qin1 and
- Yunfu Cui1Email author
© The Author(s). 2018
- Received: 5 February 2018
- Accepted: 2 April 2018
- Published: 11 April 2018
Accumulating evidence has indicated that long non-coding RNAs (lncRNAs) behave as a novel class of transcription products during multiple cancer processes. However, the mechanisms responsible for their alteration in cholangiocarcinoma (CCA) are not fully understood.
The expression of SPRY4-IT1 in CCA tissues and cell lines was determined by RT-qPCR, and the association between SPRY4-IT1 transcription and clinicopathologic features was analyzed. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays were performed to explore whether SP1 could bind to the promoter region of SPRY4-IT1 and activate its transcription. The biological function of SPRY4-IT1 in CCA cells was evaluated both in vitro and in vivo. ChIP, RNA binding protein immunoprecipitation (RIP) and luciferase reporter assays were performed to determine the molecular mechanism of SPRY4-IT1 in cell proliferation, apoptosis and invasion.
SPRY4-IT1 was abnormally upregulated in CCA tissues and cells, and this upregulation was correlated with tumor stage and tumor node metastasis (TNM) stage in CCA patients. SPRY4-IT1 overexpression was also an unfavorable prognostic factor for patients with CCA. Additionally, SP1 could bind directly to the SPRY4-IT1 promoter region and activate its transcription. Furthermore, SPRY4-IT1 silencing caused tumor suppressive effects via reducing cell proliferation, migration and invasion; inducing cell apoptosis and reversing the epithelial-to-mesenchymal transition (EMT) process in CCA cells. Mechanistically, enhancer of zeste homolog 2 (EZH2) along with the lysine specific demethylase 1 (LSD1) or DNA methyltransferase 1 (DNMT1) were recruited by SPRY4-IT1, which functioned as a scaffold. Importantly, SPRY4-IT1 positively regulated the expression of EZH2 through sponging miR-101-3p.
Our data illustrate how SPRY4-IT1 plays an oncogenic role in CCA and may offer a potential therapeutic target for treating CCA.
- Oncogenic properties
Cholangiocarcinoma (CCA) is a highly aggressive neoplasm that originates from cholangiocytes and has increasing incidence and prevalence rates . Currently, there is no effective chemoprevention or radiotherapy for CCA . Radical resection offers the only curative option, but it is suitable for only a minority of patients who are diagnosed at the early stages of the disease . What is worse, despite advances in surgical techniques and an improved understanding of the role of vascular resection and reconstruction, the 5-year survival rates after radical surgery range from 15% to 35% for CCA . For the majority of patients with unresectable tumors, the median overall survival is often less than 12 months with palliative treatment . CCA is a complex biological process that results from the dysregulation of many cancer-related genes. Therefore, an improved understanding of the molecular mechanisms underlying the pathogenesis of CCA will supply an arm for building up effective diagnostic and therapeutic targets for CCA.
Long non-coding RNAs (lncRNAs) are a class of transcribed RNA molecules longer than 200 nucleotides that have no significant protein-coding potential [6–8]. LncRNAs are involved in various biological processes, such as nuclear import, nuclear and cytoplasmic trafficking, alternative splicing and cell cycle arrest [9, 10]. A number of studies have demonstrated that the aberrant expression of lncRNAs could be critical in understanding the harmful effects of cancer on regulating cellular processes, including proliferation, metastasis and differentiation [11, 12]. Recently, several studies have demonstrated that lncRNAs can function as a molecular scaffold that interacts with proteins or RNAs to indirectly exert biological functions. For instance, enhancer of zeste homolog 2 (EZH2), a subunit of polycomb repressive complex 2 (PRC2), is a methyltransferase for histone H3 lysine 27 trimethylation (H3K27me3) . Chen et al. reported that lincRNA 00152 is involved in the transcriptional repression of IL24 and facilitates lung adenocarcinoma proliferation via binding to EZH2 . Additionally, lncRNAs can also affect post-transcriptional processing by functioning as a ‘sponge’ to absorb miRNAs. A recent study showed that MALAT1 could serve as a competing endogenous RNA (ceRNA) by sponging miR-23b-3p in gastric cancer . However, to the best of our knowledge, research regarding the involvement of lncRNAs in CCA has just begun.
SPRY4-intronic transcript 1 (SPRY4-IT1) is located at 5q31.3 and derived from an intron region within the SPRY4 gene. SPRY4-IT1 was first identified as an oncogene in melanoma cells, in which it plays a vital role in cell proliferation, apoptosis, migration and invasion . Conversely, Sun et al. found that downregulated SPRY-IT1 facilitates non-small-cell lung cancer cell proliferation and metastasis by affecting epithelial–mesenchymal transition . Liu et al. reported that SPRY4-IT1 is significantly upregulated in bladder cancer and exerts its oncogenic function by sponging miR-101-3p . Also, SPRY4-IT1 increases the proliferation of breast cancer cells by upregulating ZNF703 expression proved by a recent study . However, the expression profile, clinical features, functional role and underlying targets of SPRY4-IT1-related carcinogenesis in CCA have not been characterized.
In this study, we designed experiments to explore the expression pattern, functional role and underlying mechanisms of SPRY4-IT1 in CCA. Cell proliferation, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT) after SPRY4-IT1 silencing were assessed, which implied that SPRY4-IT1 might exert oncogenic properties in CCA. Furthermore, SPRY4-IT1 transcription could be activated by transcription factor SP1. More importantly, SPRY4-IT1 interacts with EZH2, lysine specific demethylase 1 (LSD1) and DNA methyltransferase 1 (DNMT1) and may function as a scaffold for them, thereby suppressing the underlying targets KLF2 and LATS2. SPRY4-IT1 could also positively elevate EZH2 expression levels through sponging miR-101-3p at posttranscriptional level.
Clinical specimens and cell lines
Seventy CCA tissue samples and their paired adjacent non-tumorous bile duct tissues were acquired from patients who underwent radical surgery at the Second Affiliated Hospital of Harbin Medical University between 2010 and 2012 with informed consent. This study was carried out with the approval of the Ethics Review Committees of Harbin Medical University. No local or systemic treatments were administered to these patients before surgery. The criteria for sample collection: tumor tissues contained at least 70% tumor cells, while the matched non-cancerous tissues contained no tumor cells. Complete clinic-pathological follow-up data for the patients were collected. RBE and HCCC-9810 cells were obtained commercially from the Cell Bank of Type Culture of the Chinese Academy of Sciences (Shanghai, China). Human intrahepatic biliary epithelial cell (HIBEC) and other CCA cells (CCLP-1, HuCCT1, Huh-28, KMBC and QBC939) were preserved in our laboratory. Cells were maintained in RPMI-1640 (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, CA, USA) in a humidified atmosphere at 37 °C and 5% CO2. All cell lines were passaged for no more than 6 months.
Cell transfection and RT-qPCR analysis
Short-hairpin RNA oligos directed against SPRY4-IT1 were synthesized with each containing 4 nucleotide overhangs necessary for directional cloning, Then, oligos were annealed and ligated into the shRNA vector (GeneChem, Shanghai, China). All siRNA and shRNA sequences are listed in Additional file 1: Table S1. To ectopic the expression of SP1/SPRY4-IT1/KLF2/LATS2 in CCA cells, the expression plasmid for SP1 (NM_138473), SPRY4-IT1 (NR_131221), KLF2 (NM_016270), and LATS2 (NM_014572) were PCR-amplified and subcloned into the XhoI and KpnI sites of the pcDNA3.1 vector, respectively (GeneChem, Shanghai, China). An empty pcDNA 3.1 vector was used as a control. Plasmid vectors for transfection were prepared using DNA Miniprep or Midiprep kits (Qiagen, Hilden, Germany), and transfected into cells using Lipofectamine 3000 (Thermo Fisher Scientific, USA). At 48 h post-transfection, cells were harvested for further analyses. Total RNA was isolated from tissue samples or cells using Trizol (Thermo Fisher Scientific, Waltham, MA, USA). RNA integrity number (RIN) analysis was performed using an Agilent 2100 Bioanalyser and RNA 6000 LabChip kit with Agilent 2100 Expert software (Agilent Technologies). The isolated RNA from tissue samples with a RIN of 7 or more was considered usable in the study. The Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany) was used to reverse-transcribe RNA into complementary DNA. RT-qPCR was carried out using the FastStart Universal SYBR Green Master Kit (Roche, Germany) and a BIO-RAD C1000 Thermal Cycler according to the manufacturer’s instructions. All primer sequences are summarized in Additional file 1: Table S1. We constructed standard curves prior to quantification of relative gene expression. Amplification efficiencies (E) were calculated from the slope of the standard curves according to the equation: E = 10 [− 1/slope] -1, and they ranged from 90% to 100%. The fold change of the relative expression was calculated by using the delta-delta CT method.
Cell viability and colony formation assays
Cell counting kit-8 (CCK-8) and Ki67 immunofluorescence staining assays were used to assess cell viability. Cell proliferation was documented following the manufacturer’s directions of CCK-8 kit (Dojindo, Japan) every 24 h. For the Ki67 immunofluorescence staining, transfected cells were placed in 24-well plates on cover glasses. Briefly, cells were fixed in immunostaining permeabilization buffer with Triton X-100 (Beyotime, Beijing, China) and then blocked with 5% bovine serum albumin. After the cells were incubated with anti-Ki67 monoclonal antibody (Abcam, Cambridge, MA, USA) and probed with green fluorescent-labeled secondary antibody (Solarbio, Beijing, China), an inverted fluorescence microscope (Leica, Germany) was used to observe the cells. For the clonogenic assays, a particular number of transfected cells were resuspended in a single-cell suspension and plated in six-well dishes; then, the cells were cultivated with RPMI-1640 containing 10% FBS for approximately 2 weeks until visible colonies formed. The colonies were fixed in paraformaldehyde and stained with crystal violet solution (Beyotime, Beijing, China) before observation.
Flow cytometry analyses for cell apoptosis and TdT-mediated dUTP Nick-end labeling (TUNEL) assay
Cells transfected with the indicated siRNAs and in the exponential growth phase were detached by trypsinization and resuspended in Annexin V-FITC binding buffer. Afterwards, Annexin V and propidium iodide were added to the cell suspension and incubated for 15 min at room temperature. After that, the stained cells were analyzed by using flow cytometry (FACScan, BD Biosciences). For TUNEL assay, after the cells were fixed in paraformaldehyde and treated with immunostaining permeabilization buffer with Triton X-100 (Beyotime, Beijing, China), they were incubated with 45 μl of fluorescent-labeled reagent and 5 μl of terminal deoxynucleotidyl transferase (Beyotime, Beijing, China) at 37 °C for 1 h. 4′,6-diamidino-2-phenylindole (DAPI) was used to color nuclear fractions. Finally, the cells were observed and photographed using a fluorescence microscope (Leica, Germany).
Caspase-3/9 activity assay
A caspase-3/9 activity kit (Solarbio, Beijing, China) was used for determination of caspase-3/9 activity in cell lysates following the manufacturer’s protocol.
Cell migration and invasion assays
Cell motility was measured by scratch wound assays. A 200 μL pipette tube was used to create a scraped, acellular area. Photographs were taken after 0 h and 36 h to evaluate the motility of each transfected group. Migration was quantified by counting the average distance that cells migrated towards the original wound field. Transwell migration and invasion assays were performed as previously described [20, 21]. In brief, cells were placed in serum-free RPMI-1640 medium in the upper chambers of transwell units (Costar, Washington, DC, USA) with or without 40 μL of Matrigel (BD Biosciences) coating. The lower compartments were filled with complete medium. After 24 h of incubation, cells in the upper membrane were removed with a cotton swab. The cells that traversed the membrane were fixed in 4% paraformaldehyde and stained with crystal violet solution.
Tumor xenograft study
The animal experiments were approved and reviewed by the Animal Care and Use Committee of Harbin Medical University. HuCCT1 cells were transfected with shSPRY4-IT1 or the scrambled control. After 48 h, 3 × 106 cells were injected subcutaneously into either side of the posterior flank of female BALB/c nude mice (6 weeks of age, n = 6 per group). Tumor growth was measured every 3 days, and tumor volumes were calculated using the following equation: V = 0.5 × D × d2 (V, volume; D, longitudinal diameter; d, latitudinal diameter). The mice were euthanized 18 days after injection, and the tumors weights were measured. The location and relative expression level of Ki67 was measured by the avidin-biotin-peroxidase method. In addition, total RNA was extracted from the tumors to measure the expression levels of SPRY4-IT1.
Nuclear and cytosolic fraction separation was performed using a PARIS kit (Life Technologies, Shanghai, China), according to the manufacturer’s directions.
Luciferase reporter assay
The SP1 binding motif in the promoter region of SPRY4-IT1 was identified by JASPAR (http://jaspar.genereg.net/). The different fragment sequences were synthesized and inserted into a pGL3-basic vector (Promega, Madison, WI). All vectors were verified by sequencing and luciferase activities were assessed using the Dual Luciferase Assay Kit (Promega).
RNA immunoprecipitation (RIP) assay
RIP was carried out by using the EZMagna RIP kit (Millipore, Billerica, MA, USA) according to the manufacturer’s instructions. In brief, HuCCT1 and RBE cells were lysed in RIP lysis buffer; then, the lysates were incubated with magnetic beads conjugated with specific antibodies or control IgG (Millipore). Afterwards, the beads were washed and incubated with Proteinase K to remove the proteins. At last, purified RNA was subjected to RT-qPCR analysis.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed by using the Magna ChIP Kit (Millipore, Bedford, MA) in accordance with the manufacturer’s directions. HuCCT1 and RBE cells were treated with formaldehyde to generate DNA-protein cross-links. Cell lysates were sonicated to generate chromatin fragments of 200–300 bp, and the lysates were immunoprecipitated with specific antibodies or IgG as the control. The precipitated chromatin DNA was recovered and measured by qPCR.
Western blotting and immunohistochemistry (IHC) assays
Western blot and IHC analysis were carried out following standard protocols as previously described .
Statistical analyses were performed by using GraphPad Prism 5.01 software (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS 19.0 statistical software package (IBM, Armonk, NY, USA). Significant differences between groups were evaluated by a paired, two-tailed Student’s t-tests. The results are reported as the means ± standard deviation (SD) based on at least three replicates. The relationship between SPRY4-IT1 levels and clinicopathological features was calculated by Fisher’s exact tests. Survival curves were drawn by Kaplan-Meier analyses and tested using log-rank tests. Survival data were analyzed by using univariate and multivariate Cox proportional hazards modeling. Statistical significance was set at P < 0.05.
The transcription of SPRY4-IT1 is specifically up-regulated in CCA and is related to aggressive tumor phenotypes and unfavorable prognosis
SP1 activates SPRY4-IT1 transcription in CCA cells
Knockdown of SPRY4-IT1 inhibits cell growth in vitro and in vivo
Inhibiting SPRY4-IT1 expression impairs metastatic properties by reversing EMT in CCA cells
We further explored the potential impact of SPRY4-IT1 on metastatic properties in CCA cells by using wound healing and transwell assays. Although HuCCT1 and RBE cells transfected with si-NC showed robust in vitro migration capabilities, silencing SPRY4-IT1 with either of the two siRNAs dramatically impaired the wound closure potential (Fig. 4a). Consistent with our predictions, transwell experiments revealed significantly decreased migration and invasive capabilities in the si-SPRY4-IT1–1 and si-SPRY4-IT1–2 groups (Fig. 4b and c). Cell migration and invasion are essential prerequisites for cancer metastasis, and EMT is a pivotal mechanism that is correlated with cell invasive capabilities. To assess whether SPRY4-IT1 was also involved in the EMT in CCA, the expression levels of EMT-related proteins were evaluated in HuCCT1 and RBE cells after transfected with the indicated siRNAs. Western blot analyses showed that silencing SPRY4-IT1 increased the expression levels of E-cadherin and decreased the expression levels of Snail and vimentin (Fig. 4d).
SPRY4-IT1 represses KLF2 and LATS2 expression by scaffolding EZH2, LSD1 and DNMT1
SPRY4-IT1 functions as a ceRNA and sponges miR-101-3p in CCA cells
Interestingly, previous publication reported that SPRY4-IT1 positively regulates posttranscriptional expression of EZH2 by sponging miR-101-3p in bladder cancer . In the present study, our findings showed that the expression of miR-101-3p is strongly affected by SPRY4-IT1 expression in CCA cells (Additional file 6: Figure S3A and B). EZH2 was also downregulated after SPRY4-IT1 knockdown or miR-101-3p overexpression (Additional file 6: Figure S3C and D). Then, we mutated the miR-101-3p binding site in SPRY4-IT1 by site-directed mutagenesis. As expected, the miR-101-3p mediated suppression of luciferase activity was abolished in this mutated SPRY4-IT1 construct compared with the wild-type vector (Additional file 6: Figure S3E). In addition, EZH2 was identified as a target of miR-101-3p by luciferase reporter assay (Additional file 6: Figure S3F). Furthermore, increased expression of miR-101-3p impaired CCA cell proliferation and invasive capabilities (Additional file 6: Figure S3G and H). Collectively, these results demonstrate that SPRY4-IT1 functions as a ceRNA for miR-101-3p, thereby derepresses EZH2 expression in CCA.
SPRY4-IT1 oncogenic properties are partly dependent on repressing KLF2 and LATS2 expression
Currently, radical operation and chemoradiotherapy, which are comprehensive treatments, have become the core approaches for treating CCA. Although these types of treatment can prolong lifespan and alleviate patient suffering, the prognosis for CCA remains poor [23, 24]. Recently, lncRNAs have emerged as crucial regulators of gene expression and key players in multiple cancers . For example, increased levels of GAS5 can inhibit gastric cancer cell proliferation and induce apoptosis both in vitro and in vivo . In addition, a number of lncRNAs, including MALAT1 and AFAP1-AS1, have been reported to be involved in CCA cell growth and metastasis [27–29]. In the current study, we focused on a novel cancer-associated lncRNA, SPRY4-IT1, whose expression levels are distinctly higher in CCA tissues than non-tumorous tissues. Aberrant expression levels of SPRY4-IT1 were correlated with tumor stage and TNM stage. Besides, SPRY4-IT1 could serve as an independent prognostic indicator for CCA patients proved by multivariate Cox regression analyses. The findings above suggest that SPRY4-IT1 may function as an oncogene and play a critical role in CCA development and progression. On the contrary, SPRY4-IT1 seems down-regulated in non-small-cell lung cancer and acts as a potential tumor suppressor , which suggests that SPRY4-IT1 may exert an oncogene or tumor suppressor function depending on the tissue-specific expression pattern and circumstances.
Recently, emerging evidence indicated that the expression of lncRNAs can be regulated by transcription factors just like some protein coding genes. For example, transcription factor E2F1 activates lncRNA HOXA11-AS transcription in gastric cancer . In the present study, SPRY4-IT1 upregulation in CCA could be activated by SP1. Subsequent in vitro and in vivo studies indicated that SPRY4-IT1 silencing significantly inhibited malignant biological phenotypes of CCA cells. SPRY4-IT1 protected against cell apoptosis partly through Bcl-2/caspase-3 pathway. EMT, a major mechanism involved in tumor metastasis, causes the loss of cell-cell adhesion and increases migration and invasion capabilities . E-cadherin is directly suppressed by Snail, which in turn induces EMT in epithelial tumor cells . Here, we found a decrease in migration and invasion potentials after SPRY4-IT1 was silenced partly by reversing Snail mediated EMT. Herein, the SPRY4-IT1/Snail/E-cadherin axis may play a critical role in facilitating CCA metastatic properties.
After validating the role of SPRY4-IT1 as an oncogene in CCA, we explored the molecular mechanisms underlying the altered malignant phenotypes. Currently, several lncRNAs have been well characterized; these lncRNAs can modulate gene expression via various mechanisms, including chromatin modification, transcription and post-transcriptional processing. Recently, evidence has demonstrated that several lncRNAs regulate downstream effectors via interacting with RNA binding proteins such as EZH2, SUZ12, LSD1, STAU1, DNMT1 et al. [33, 34]. Previous publication has reported that EZH2-driven H3K27 methylation and LSD1 mediated H3K4 demethylation at the transcriptional level can be regulated by lncRNAs . In our study, there is a direct interaction between SPRY4-IT1 and EZH2, LSD1 and DNMT1 in HuCCT1 and RBE cells. Further RT-qPCR analysis and correlation analysis showed that RND1, KLF2 and LATS2 may be novel targets of SPRY4-IT1 in CCA. However, silencing of EZH2, LSD1 or DNMT1 did not affect the expression of RND1 but enhanced KLF2 and LATS2 expression in HuCCT1 and RBE cells. The fact above suggested that SPRY4-IT1 may regulate RND1 through other mechanisms. Importantly, ChIP assays determined that SPRY4-IT1 could recruit EZH2 and DNMT1 to KLF2 promoter region and recruit EZH2 and LSD1 to LATS2 promoter region, respectively, and inhibit their transcription. KLF2, a tumor suppressor and member of the KLF family, contains Cys2/His2 zinc finger motifs and acts as transcription factors to regulate downstream targets including cyclin-dependent kinase genes . Its expression is suppressed in various carcinomas, such as non-small cell lung cancer and pancreatic ductal adenocarcinoma [37, 38]. LATS2 is a key member of the Hippo pathway and functions as a tumor suppressor owing to its role in the suppression of cell growth and silencing the transcriptional co-activators YAP and TAZ . It is frequently reduced in malignancies such as breast cancer and mesothelioma [40, 41]. In the current study, our findings showed that KLF2 and LATS2 functioned as a tumor suppressor in CCA. Importantly, rescue experiments determined that the oncogenic function of SPRY4-IT1 is partly depends on repressing KLF2 and LATS2 expression. These findings implied that SPRY4-IT1 may indirectly influence downstream targets of KLF2 and LATS2 such as cyclin-dependent kinase and Hippo pathway to exert oncogenic properties in CCA. In our study, SPRY4-IT1 RNAs were also located in the cytoplasm, which made us to investigate whether SPRY4-IT1 may play a role at post-transcriptional level in CCA. As we expected, SPRY4-IT1 acts as a ceRNA for miR-101-3p in CCA, and binding with miR-101-3p releases its inhibition of EZH2 mRNA, resulting in elevated EZH2 protein levels. EZH2 could then enter into the nucleus, which could further be recruited by SPRY4-IT1 to repress KLF2 and LATS2 transcription (Fig. 6k). In the present study, other possible targets and mechanisms underlying the regulatory actions were not explored sufficiently and a larger cohort of patients should be recruited to further validate the clinical value of SPRY4-IT1.
In summary, our study first revealed that SPRY4-IT1 is upregulated in human CCA tissues and cells, and its overexpression may be an unfavorable prognostic factor for patients with CCA. SP1 could bind directly to the SPRY4-IT1 promoter region and activate its transcription. In addition, SPRY4-IT1 silencing yielded tumor suppressive effects both in vitro and in vivo. Importantly, the oncogenic effects of SPRY4-IT1 may occur via its binding to EZH2, LSD1 and DNMT1 to induce the epigenetic silencing of KLF2 and LATS2 transcription. SPRY4-IT1 also functioned as a molecular sponge for miR-101-3p, antagonizing its ability to repress EZH2 protein translation. Ultimately, these results may expedite the appraisal of novel predictive or therapeutic targets for CCA.
This study was supported by National Natural Science Foundation of China (Grant No. 81602088 and 81170426), China Postdoctoral Science Foundation (Grant No. 2017 M621305), Heilongjiang Postdoctoral Science Foundation (Grant No. LBH-Z16096), Health and Family Planning Commission Research Project of Heilongjiang Province (Grant No. 2016–049), Postgraduate innovative research project of Harbin Medical University (Grant No. YJSCX2016-21HYD), Innovative Science Foundation of Harbin Medical University (Grant No. 2016LCZX09) and Natural Science Foundation of Heilongjiang Province (Grant No. H201396).
Availability of data and materials
The datasets supporting the findings of this study are included within the article.
YFC designed this study. YX, YY, XYZ, ZDW and CLL did the assays in vitro. XMJ, PCK, KML and DLJ did the assays in vivo. YFC, ZLL and LNH collected clinical samples. YX, XMJ and WQ analyzed the data. YX and YY wrote the manuscript. All authors read and approved the final manuscript.
The research protocol was reviewed and approved with the approval of the Ethics Review Committees of Harbin Medical University, and written informed consent was obtained from each patient included in the study. All procedures involving animals were performed according to the guidelines of the Association for the Assessment and Accreditation of Laboratory Animal Care International.
Consent for publication
No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, Chari ST, Martenson JA. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc. 2007;82:628–37.View ArticlePubMedGoogle Scholar
- De Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L, Ferrone CR, Zhu AX, Bauer TW, Walters DM, Gamblin TC, Nguyen KT, Turley R, Popescu I, Hubert C, Meyer S, Schulick RD, Choti MA, Gigot JF, Mentha G, Pawlik TM. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–5.View ArticlePubMedGoogle Scholar
- Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, Youssef BAM, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma. 1990-2009. World J Gastroenterol. 2009;15:4240–62.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, Regev A, Rinn JL, Root DE, Lander ES. LincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477:295–300.View ArticlePubMedPubMed CentralGoogle Scholar
- Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.View ArticlePubMedGoogle Scholar
- Xu LM, Chen L, Li F, Zhang R, Li ZY, Chen FF, Jiang XD. Over-expression of the long non-coding RNA HOTTIP inhibits glioma cell growth by BRE. J Exp Clin Cancer Res. 2016;35:162.View ArticlePubMedPubMed CentralGoogle Scholar
- Lv J, Qiu M, Xia W, Liu C, Xu Y, Wang J, Leng X, Huang S, Zhu R, Zhao M, Ji F, Xu L, Xu K, Yin R. High expression of long non-coding RNA SBF2-AS1 promotes proliferation in non-small cell lung cancer. J Exp Clin Cancer Res. 2016;35:75.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen ZH, Wang WT, Huang W, Fang K, Sun YM, Liu SR, Luo XQ, Chen YQ. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ. 2017;24:212–24.View ArticlePubMedGoogle Scholar
- Xu CZ, Jiang C, Wu Q, Liu L, Yan X, Shi R. A feed-forward regulatory loop between HuR and the long noncoding RNA HOTAIR promotes head and neck squamous cell carcinoma progression and metastasis. Cell Physiol Biochem. 2016;40:1039–51.View ArticlePubMedGoogle Scholar
- Conway E, Healy E, Bracken AP. PRC2 mediated H3K27 methylations in cellular identity and cancer. Curr Opin Cell Biol. 2015;37:42–8.View ArticlePubMedGoogle Scholar
- Chen QN, Chen X, Chen ZY, Nie FQ, Wei CC, Ma HW, Wan L, Yan S, Ren SN, Wang ZX. Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression. Mol Cancer. 2017;16:17.View ArticlePubMedPubMed CentralGoogle Scholar
- YiRen H, YingCong Y, Sunwu Y, Keqin L, Xiaochun T, Senrui C, Ende C, XiZhou L, Yanfan C. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16:174.View ArticlePubMedPubMed CentralGoogle Scholar
- Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, Perera RJ. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011;71:3852–62.View ArticlePubMedGoogle Scholar
- Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, Yang JS, Xu TP, Liu YW, Zou YF, Lu BB, Yin R, Zhang EB, Xu L, De W, Wang ZX. EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. Cell Death Dis. 2014;5:e1298.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu D, Li Y, Luo G, Xiao X, Tao D, Wu X, Wang M, Huang C, Wang L, Zeng F, Jiang G. LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer Lett. 2017;388:281–91.View ArticlePubMedGoogle Scholar
- Shi Y, Li J, Liu Y, Ding J, Fan Y, Tian Y, Wang L, Lian Y, Wang K, Shu Y. The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression. Mol Cancer. 2015;14:51.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu Y, Wang Z, Jiang X, Cui Y. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition. Biomed Pharmacother. 2017;92:17–23.View ArticlePubMedGoogle Scholar
- Xu Y, Yao Y, Leng K, Li Z, Qin W, Zhong X, Kang P, Wan M, Jiang X, Cui Y. Long non-coding RNA UCA1 indicates an unfavorable prognosis and promotes tumorigenesis via regulating AKT/GSK-3β signaling pathway in cholangiocarcinoma. Oncotarget. 2017;8:96203–14.PubMedPubMed CentralGoogle Scholar
- Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G. LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-mediated H3K4me2 demethylation. Mol Cancer. 2017;16:39.View ArticlePubMedPubMed CentralGoogle Scholar
- Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8:14192–220.PubMedGoogle Scholar
- Miyazaki Y, Kokudo T, Amikura K, Kageyama Y, Takahashi A, Ohkohchi N, Sakamoto H. Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature. Jpn J Clin Oncol. 2017;47:206–12.View ArticlePubMedGoogle Scholar
- Kwok ZH, Tay Y. Long noncoding RNAs: lincs between human health and disease. Biochem Soc Trans. 2017;45:805–12.View ArticlePubMedGoogle Scholar
- Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP, Liu YW, Zhang EB, Liu XH, De W. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer. 2014;14:319.View ArticlePubMedPubMed CentralGoogle Scholar
- Tan X, Huang Z, Li X. Long non-coding RNA MALAT1 interacted with miR-204 to modulate human hilar cholangiocarcinoma proliferation, migration and invasion by targeting CXCR4. J Cell Biochem. 2017;118:3643–53.View ArticlePubMedGoogle Scholar
- Shi X, Zhang H, Wang M, Xu X, Zhao Y, He R, Zhang M, Zhou M, Li X, Peng F, Shi C, Shen M, Wang X, Guo X, Qin R. LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells. Oncotarget. 2017;8:58394–404.PubMedPubMed CentralGoogle Scholar
- Lu X, Zhou C, Li R, Deng Y, Zhao L, Zhai W. Long noncoding RNA AFAP1-AS1 promoted tumor growth and invasion in cholangiocarcinoma. Cell Physiol Biochem. 2017;42:222–30.View ArticlePubMedGoogle Scholar
- Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, Xie M, Xu L, De W, Wang Z, Wang J. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res. 2016;76:6299–310.View ArticlePubMedGoogle Scholar
- Ye X, Weinberg RA. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 2015;25:675–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, Evers BM, Zhou BP. G9a interacts with snail and is critical for snail mediated E-cadherin repression in human breast cancer. J Clin Invest. 2012;122:1469–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Benetatos L, Voulgaris E, Vartholomatos G, Hatzimichael E. Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. Int J Cancer. 2013;133:267–74.View ArticlePubMedGoogle Scholar
- Huang M, Hou J, Wang Y, Xie M, Wei C, Nie F, Wang Z, Sun M. Long noncoding RNA LINC00673 is activated by SP1 and exerts oncogenic properties by interacting with LSD1 and EZH2 in gastric cancer. Mol Ther. 2017;25:1014–26.View ArticlePubMedPubMed CentralGoogle Scholar
- Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329:689–93.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu TP, Liu XX, Xia R, Yin L, Kong R, Chen WM, Huang MD, Shu YQ. SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. Oncogene. 2015;34:5648–61.View ArticlePubMedGoogle Scholar
- Yin L, Wang JP, Xu TP, Chen WM, Huang MD, Xia R, Liu XX, Kong R, Sun M, Zhang EB, Shu YQ. Downregulation of Kruppellike factor 2 is associated with poor prognosis for non-small cell lung cancer. Tumor Biol. 2014;36:3075–84.View ArticleGoogle Scholar
- Zhang D, Dai Y, Cai Y, Suo T, Liu H, Wang Y, Cheng Z, Liu H. KLF2 is downregulated in pancreatic ductal adenocarcinoma and inhibits the growth and migration of cancer cells. Tumor Biol. 2016;37:3425–31.View ArticleGoogle Scholar
- Visser S, Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle. 2010;9:3892–903.View ArticlePubMedGoogle Scholar
- Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. 2005;11:1380–5.View ArticlePubMedGoogle Scholar
- Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71:873–83.View ArticlePubMedGoogle Scholar